Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term open-label extension study of oral dersimelagon in EPP or XLP
jRCT2041210146Phase 3Active, not recruiting
- Sponsor
- Mitsubishi Tanabe Pharma Corporation
- Start
- May 2022
- Modality
- Small Molecules
01
Overview
Phase 3, open-label, single-arm trial of dersimelagon in erythropoietic protoporphyria (EPP) and X-linked protoporphyria (XLP), sponsored by Mitsubishi Tanabe Pharma Corporation. Primary endpoints: Number of patients with treatment-emergent adverse events, Number of patients with abnormal physical examination data and 1 more. Started May 2022; status: active, not recruiting.
02
Drugs
dersimelagon
03
Conditions
erythropoietic protoporphyria (EPP)X-linked protoporphyria (XLP)
Beyond the preview
Go deeper on jRCT2041210146.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2041210146.